ClinicalTrials.gg
RecruitingNCT07039019PROSPECTUpdated Jun 25, 2026

Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis

An Early Phase 1 interventional study of Corticosteroid and No Corticosteroid in Pleuritis, Non-specific, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Icahn School of Medicine at Mount Sinai · Early Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This research study aims to evaluate whether corticosteroids help prevent the recurrence of pleural effusions in patients with non-specific pleuritis diagnosed through pleural biopsy. It can lead to recurrent fluid buildup in the lungs, causing discomfort and requiring additional medical interventions. There is no established treatment to prevent recurrence, and this study seeks to determine whether steroids reduce fluid buildup or cause complications.

There will be two groups: one receiving corticosteroids (standard of care in the institution) and one not receiving corticosteroids (intervention group). The participation will last approximately 6 months, with in-person visits every 2 weeks for the first month, then monthly, along with possible telephone follow-ups. The study will monitor for pleural effusion recurrence, need for additional procedures, and potential side effects of corticosteroids.

This is a pilot study. Although there are forty people expected to take part in this research study based on institutional data, the number of patients included in the study will be determined by the number of patients with non-specific pleuritis diagnosed during the study period.

02

Conditions studied

  • Pleuritis, Non-specific
03

In context

Lead sponsor

Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.

Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult patients with diagnosis of non-specific pleuritis as determined by pleural with a negative serologic profile (ANA, ANCA, anti-DS DNA, anti-SS A/B, anti-centromere, RF, anti-CCP) are eligible

Exclusion criteria

Exclusion Criteria:

  • Chronic/fibrinous pleuritis
  • Positive serologic workup
  • A to
  • Empyema
  • Patients already receiving corticosteroids or other medications for any other indication
  • Inability to obtain due to cognitive, neurologic or psychiatric impairment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Patients with Corticosteroids

    Standard of care (corticosteroids) as per institutional practice. If the treatment is effective, patients continue for another 4 weeks while taking medication to prevent infections. If it's not effective, they begin a gradual dose reduction until stopping.

    Drug: Corticosteroid

  • Active comparator
    Patients with No Corticosteroids

    Patients will not receive any corticosteroids.

    Other: No Corticosteroid

Interventions

  • DrugCorticosteroid

    Patients take 40 mg of prednisone daily for 4 weeks to help reduce inflammation.

    Also known as: Prednisone

  • OtherNo Corticosteroid

    Patients do not take corticosteroid.

06

What researchers measure

Primary outcomes

  1. Number of patients screened

    Screened defined as how many patients are evaluated for participation

    Time frame: every 2 weeks after pleuroscopy for the first 4 weeks, and then monthly up to 6 months

  2. Number of patients enrolled

    Enrolled defined as how many screened patients actually join the study

    Time frame: every 2 weeks after pleuroscopy for the first 4 weeks, and then monthly up to 6 months

  3. Number of patients retained

    Retention defined as how many enrolled patients continue participating over time

    Time frame: every 2 weeks after pleuroscopy for the first 4 weeks, and then monthly up to 6 months

Secondary outcomes

  1. Rate of recurrence

    Incidence of recurrent pleural effusions attributable to symptoms requiring an intervention

    Time frame: every 2 weeks after pleuroscopy for the first 4 weeks, and then monthly up to 6 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication.

Access criteria: Researchers who provide a methodologically sound proposal. To achieve aims in the approved proposal. Proposals should be directed to udit.chaddha@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (link to be determined).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jun 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 26, 2025
StartActual
May 29, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07039019
Responsible party
Udit Chaddha (Associate Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jun 26, 2025
Start date
May 29, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Axel Duval, MD
Contact
axel.duval@mountsinai.org
212-824-8546
Udit Chaddha, MBBS
principal investigator · Icahn School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion